Abstract:
A process including: (a) selecting a composition including a polymer and a liquid, wherein the polymer exhibits lower solubility in the liquid at room temperature but exhibits greater solubility in the liquid at an elevated temperature, wherein the composition gels when the elevated temperature is lowered to a first lower temperature without agitation; (b) dissolving at the elevated temperature at least a portion of the polymer in the liquid; (c) lowering the temperature of the composition from the elevated temperature to the first lower temperature; (d) agitating the composition to disrupt any gelling, wherein the agitating commences at any time prior to, simultaneous with, or subsequent to the lowering the elevated temperature of the composition to the first lower temperature: (e) depositing a layer of the composition wherein the composition is at a second lower temperature lower than the elevated temperature; and (f) drying at least partially the layer.
Abstract:
A polythiophene wherein the monomer segments thereof contain: wherein A is a side chain; B is hydrogen or a side chain; and D is a divalent segment, and wherein the number of A-substituted thienylene units (I) in the monomer segments is from about 1 to about 10, the number of B-substituted thienylene units (II) is from 0 to about 5, and the number of divalent segments D is 0 or 1.
Abstract:
A thienylene-arylene polymer comprised of a repeating segment containing at least one 2,5-thienylene unit selected from (I) and (II), and from about one to about three arylene units selected from (IIIa), (IIIb), and/or (IIIc) wherein R is an alkyl or an alkoxy; R′ is halogen, alkyl, or alkoxy, and a and b represent the number of Rs.
Abstract:
Catalyst materials having a surface comprising a composition Mx/Pty/Sub; wherein M is selected from the group of elements Fe, Co, Rh and Ir; or wherein M represents two different elements selected from the group comprising Fe, Co, Rh, Ir, Ni, Pd, Cu, Ag, Au and Sn; and wherein Sub represents a substrate material selected from Ru and Os; the respective components being present within specific ranges, display improved properties for use in anodes for low-temperature fuel cell anodes for PEMFC fuel cells and direct methanol fuel cells.
Abstract:
A charge transport composition containing aromatic amines with crosslinkable silanes as represented by the formula wherein A represents a hole transporting aromatic tertiary amine moiety; L1 and L2 represents charge such as a divalent group; X represents oxygen or an imino group; Y represents an alkoxy group, or a halide atom; R is a hydrogen atom or an alkyl group; and n represents the number of repeating segments.
Abstract:
In a synchronous code division multiple access (SCDMA) time division duplex (TDD) communication system, a remote terminal uses both open loop and closed loop techniques for synchronization with a base station. The timing of reception of information by tile remote terminal is performed with an open loop technique, while the timing of transmissions from the terminal is performed with a closed loop technique. Furthermore, a clock locked loop in the terminal compensates for differences between clocks of the terminal and the base station. The clock locked loop responds to signals from both the aforesaid open loop and closed loop techniques.
Abstract:
An improved method is provided to secure a suture relative to body tissue. A suture retainer is moved along first and second sections of a suture toward the body tissue. When a predetermined minimum force is being transmitted between the suture retainer and the body tissue, the first and second sections of the suture are gripped with the suture retainer by plastically deforming material of the suture retainer. The material of the suture retainer cold flows under the influence of force applied against the surface areas on the suture retainer. One or more bends are formed in each of the sections of the suture to increase the holding action between the suture retainer and the sections of the suture. The bends may be formed by wrapping a turn of the suture around a portion of the suture retainer. During movement of the suture retainer toward the body tissue, the bends are moved along the first and second sections of the suture.
Abstract:
An improved system and method for determining and tracking the carrier offset in a communications system. In an exemplary implementation, sampled spread spectrum digital signals are compensated with an expected carrier offset and stripped of pseudo-noise codes to produce demodulated signals. The demodulated signals are applied to a carrier offset estimator. The carrier offset estimator divides pairs of demodulated signals with a predetermined interval to produce results containing phase change information. The results are then averaged, and the average is normalized with respect to the predetermined interval to yield a new estimate of the carrier offset. The expected carrier frequency is adjusted based on the new offset estimate for frequency compensation in subsequent reception and transmission operations.
Abstract:
An organic electroluminescent (EL) device comprised of a starburst aromatic amine compound represented by the formula ##STR1## wherein N is nitrogen; A.sup.1 to A.sup.3 each individually represent biaryl; R.sub.a, R.sub.b, and R.sub.c represent independently one of the functional groups of the following formulae ##STR2## wherein N is nitrogen; each Ar.sup.1 and Ar.sup.2 are aryl; R.sub.1 to R.sub.8 are substituents independently selected from the group consisting of hydrogen, halogen, hydrocarbon, and alkoxy; and X represents oxygen, sulfur, or an alkylene.
Abstract translation:一种有机电致发光(EL)装置,其由式(I)表示的星形芳族胺化合物,其中N为氮; A1至A3各自独立地表示联芳基; R a,R b和R c分别独立地表示下式的官能团之一:其中N是氮; 每个Ar1和Ar2是芳基; R 1至R 8为独立地选自氢,卤素,烃和烷氧基的取代基; X表示氧,硫或亚烷基。
Abstract:
The present invention is directed to substituted certain reversed indazolyl-spiro[2.2]pentane-carbonitrile derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, X, Y, and Z are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.